Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluprostenol is a synthetic analogue of prostaglandin F2alpha and an organofluorine compound in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. It acts as a potent and highly selective agonist of the Prostaglandin F2-alpha receptor (FP receptor). Fluprostenol has roles as an antiglaucoma drug, antihypertensive agent, female contraceptive drug, and abortifacient. Its primary mechanism involves activation of the FP receptor leading to phospholipase C activation and increased intracellular calcium via Gq protein signaling[1][4][6]. Ophthalmic solutions of its isopropyl ester prodrug (travoprost) are used for reducing intraocular pressure in open-angle glaucoma and ocular hypertension[1][7]. In veterinary medicine (notably in mares), it is used for its luteolytic effect to control estrus timing[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluprostenol.